Page 251 - index.html
P. 251

P07.06


          ASS1 IMMUNOHISTOCHEMISTRY IDENTIFIES
          UNCLASSIFIED HEPATOCELLULAR ADENOMA.
          EXPERIENCE OF A SINGLE FRENCH LIVER CENTER

                                                                    4
                              1, 2
          Anne-Aurélie Raymond , Jean-Frédéric Blanc , Jean-William Dupuy , Brigitte
                                                 1, 3
          Le Bail , Nathalie Dugot-Senant , Charles Balabaud , Paulette Bioulac-Sage * 1,
                                                      1
                1, 5
                                      6
          5 , Frédéric Saltel 1, 2
                                                                      3
          1 Bariton Inserm 1053, Bordeaux, France,  Oncoprot, INSERM 1053, Bordeaux, France,  Service
                                      2
          Hépatologie Gastroentérologie et Oncologie Digestive, Hôpital Haut Lévêque, CHU Bordeaux,
          4 Plateforme Protéome, Centre de Génomique Fonctionnelle de Bordeaux, Université de Bordeaux,
          Bordeaux, France,  Service de pathologie, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France,
                       5
          6 Plateforme d’histopathologie, INSERM 005, Bordeaux, France, Bordeaux, France
          Corresponding author’s email: charles.balabaud@u-bordeaux.fr
          Introduction: In our center all hepatocellular adenoma (HCA) are classified routinely
          by immunohistochemistry. Unclassified HCA (UHCA) are defined by default (HCA
          markers negative).                                                   ePOSTER ABSTRACTS

          Aims:  To  test  UHCA  with  ASS1  antibodies  (a  protein  belonging  to  the  Arginine
          metabolic pathway), a marker identified by proteomic analysis in UHCA and to correlate
          with clinicopathological data.
          Material and Methods: From a total of 218 resected cases (189F/29M) there were 70
          H-HCA, 69 IHCA, 22 b-HCA [15 ex3], 32 b-IHCA [19 ex3], 15 UHCA and 10 not
          classifiable (massive hemorrhage/necrosis in 8 cases, waiting identification in 2 cases).
          ASS1 IHC was performed in all UHCA, 3 HCA of each other subtype and 3 focal nodular
          hyperplasia (FNH).

          Results: All 15 UHCA were women, mean age 40 (range 27-48); all on oral contraceptives,
          mean of 22 years (range 11-30) in 10/15 cases. BMI was raised in 11 cases, mean 30
          (range 19.7- 45.7). Mode of discovery was death by hemorrhagic rupture of the liver,
          severe hemorrhage (intratumoral, intrahepatic, or peritoneal), pain, and chance in 1, 5,
          6, and 3 cases respectively.The number of nodules was 1, 2, or ≥ 5 in 9, 4 and 2 cases
          respectively. Associated diseases were diabetes type 2, arterial hypertension in 4 and 3
          cases (one of renal origin) respectively. Non tumoral liver (NT) was steatotic in 10 cases:
          ≥ 60%, 30-60%, 10-30% in 6, 2 and 2 cases respectively. Areas of hemorrhage, small or


          EASL HCC Summit  •  Geneva, Switzerland  •  2-5 February, 2017  251
   246   247   248   249   250   251   252   253   254   255   256